Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity happened following the announcement that an Advisory Committee meeting will soon review the firm’s New Drug Application (NDA) for Dsuvia (Sufentanil) developed for the management of moderate-to-severe acute pain in medically supervised settings in adult patients.

Sufentanil is an opioid analgesic currently marketed for intravenous (IV) and epidural anesthesia and analgesia. When sufentanil is delivered sublingually, its pharmacokinetic profile avoids the high peak plasma levels and short duration of action observed . . .